Thiard News@F4F

@newsen.bsky.social

3 days ago

Nomination Committee Proposes Members for Board of BioArctic AB Ahead of Upcoming Election BioArctic AB's Nomination Committee has proposed eight candidates for its Board, including prominent experts in neurodegenerative diseases ahead of the annual meeting.

Nomination Committee Proposes Members for Board of BioArctic AB Ahead of Upcoming Election #Sweden #Stockholm #BioArctic #Philip_Scheltens #Linda_Nilsson

Thiard News@F4F

@newsen.bsky.social

1 week ago

New Insights on Lecanemab Emerge at the 2026 AD/PD™ Conference for Alzheimer’s Treatment Recent data presented at the 2026 AD/PD™ congress highlights the effectiveness of lecanemab in long-term Alzheimer's treatment, showing promising patient adherence.

New Insights on Lecanemab Emerge at the 2026 AD/PD™ Conference for Alzheimer’s Treatment #Sweden #Stockholm #Lecanemab #Eisai #BioArctic

Thiard News@F4F

@newsen.bsky.social

1 week ago

New Insights on Long-Term Efficacy of Lecanemab Presented at 2026 AD/PD Congress At the 2026 AD/PD congress, BioArctic and Eisai unveiled significant findings on the long-term usage of lecanemab for Alzheimer's treatment, highlighting patient adherence.

New Insights on Long-Term Efficacy of Lecanemab Presented at 2026 AD/PD Congress #Sweden #Copenhagen #Lecanemab #Eisai #BioArctic

Thiard News@F4F

@newsen.bsky.social

2 weeks ago

Presentation of Long-Term Lecanemab Treatment Data at AD/PD 2026 Congress BioArctic's partner Eisai will unveil pivotal long-term data on lecanemab at the AD/PD 2026 congress, detailing its efficacy and safety in treating Alzheimer's disease.

Presentation of Long-Term Lecanemab Treatment Data at AD/PD 2026 Congress #Sweden #Copenhagen #Lecanemab #Eisai #BioArctic

Thiard News@F4F

@newsen.bsky.social

1 month ago

BioArctic AB's Recent Share Issuance and Vote Statistics Explained BioArctic AB recently announced a substantial issuance of Class B shares, marking a critical step in their ongoing stock option program. Learn more about their voting shares.

BioArctic AB's Recent Share Issuance and Vote Statistics Explained #Sweden #Stockholm #Class_B_shares #stock_options #BioArctic

Thiard News@F4F

@newsen.bsky.social

1 month ago

BioArctic AB Reports Increase in Shares and Voting Rights as of Late February 2026 BioArctic AB has issued 78,000 Class B shares, bringing their total to over 88 million, enhancing voting rights as of February 27, 2026.

BioArctic AB Reports Increase in Shares and Voting Rights as of Late February 2026 #Sweden #Stockholm #Leqembi #BioArctic #Nasdaq_Stockholm

Thiard News@F4F

@newsen.bsky.social

1 month ago

BioArctic's Leqembi® Receives Priority Review for New Subcutaneous Formulation in China Leqembi® (lecanemab) has been granted Priority Review status for its subcutaneous formulation by China's NMPA. This could transform treatment options for Alzheimer's patients.

BioArctic's Leqembi® Receives Priority Review for New Subcutaneous Formulation in China #China #Beijing #Eisai #Leqembi #BioArctic

Thiard News@F4F

@newsen.bsky.social

1 month ago

Leqembi® Achieves Major Sales Milestone of 20.7 Billion Yen in Q4 2025 Leqembi® generated impressive sales of 20.7 billion yen in the fourth quarter of 2025, marking a significant increase and highlighting its market strength.

Leqembi® Achieves Major Sales Milestone of 20.7 Billion Yen in Q4 2025 #Sweden #Stockholm #Eisai #Leqembi #BioArctic

Thiard News@F4F

@newsen.bsky.social

1 month ago

Leqembi® Sales Surge to 20.7 Billion Yen in Q4 2025 Amidst Collaboration Success Leqembi® has reported remarkable sales of 20.7 billion yen in Q4 2025, showcasing significant growth amid BioArctic and Eisai’s collaboration efforts.

Leqembi® Sales Surge to 20.7 Billion Yen in Q4 2025 Amidst Collaboration Success #Sweden #Stockholm #Eisai #Leqembi #BioArctic

Thiard News@F4F

@newsen.bsky.social

2 months ago

Eisai Submits New Marketing Application for Leqembi® with Extended Dosing Schedule Eisai has submitted a Marketing Authorisation Variation to EMA for Leqembi® to allow intravenous maintenance dosing every four weeks, enhancing treatment options.

Eisai Submits New Marketing Application for Leqembi® with Extended Dosing Schedule #Eisai #Leqembi #BioArctic

Thiard News@F4F

@newsen.bsky.social

2 months ago

Eisai's New Subcutaneous Formulation of Leqembi® Accepted for Review in China Eisai’s Biologics License Application for subcutaneous Leqembi® has been accepted in China, potentially revolutionizing Alzheimer's treatment options.

Eisai's New Subcutaneous Formulation of Leqembi® Accepted for Review in China #China #Beijing #Eisai #Leqembi #BioArctic

Thiard News@F4F

@newsen.bsky.social

3 months ago

Eisai's Leqembi® Added to China's Innovative Drug Insurance List, Expanding Alzheimer's Treatment Options Eisai's Leqembi® has been officially included in China's Innovative Drug Insurance List, enhancing access to early Alzheimer's treatment for millions.

Eisai's Leqembi® Added to China's Innovative Drug Insurance List, Expanding Alzheimer's Treatment Options #China #N/A #Eisai #Leqembi #BioArctic

Thiard News@F4F

@newsen.bsky.social

3 months ago

New Leqembi Data Shows Promising Results in Delaying Alzheimer's Disease Progression by 8.3 Years Recent findings from the CTAD 2025 conference reveal that Leqembi treatment may delay Alzheimer's progression by up to 8.3 years, marking a significant advance in Alzheimer's care.

New Leqembi Data Shows Promising Results in Delaying Alzheimer's Disease Progression by 8.3 Years #Sweden #Stockholm #Eisai #Leqembi #BioArctic

Thiard News@F4F

@newsen.bsky.social

4 months ago

Upcoming Presentation Reveals New Insights on Lecanemab at CTAD Conference At the upcoming CTAD conference, Eisai will unveil significant new data on lecanemab, focusing on its long-term benefits and safety measures for Alzheimer's treatment.

Upcoming Presentation Reveals New Insights on Lecanemab at CTAD Conference #Sweden #Stockholm #Lecanemab #Eisai #BioArctic

Thiard News@F4F

@newsen.bsky.social

4 months ago

New Insights on Lecanemab to Be Revealed at CTAD Conference in San Diego Eisai will unveil new findings on lecanemab at the upcoming CTAD conference in San Diego, focusing on long-term treatment benefits and safety.

New Insights on Lecanemab to Be Revealed at CTAD Conference in San Diego #Sweden #Stockholm #Lecanemab #Eisai #BioArctic

Thiard News@F4F

@newsen.bsky.social

4 months ago

UK Approves Leqembi for Long-Term Alzheimer's IV Treatment Leqembi, a new treatment for early Alzheimer's, has been approved for intravenous maintenance dosing in the UK, enhancing patient care options.

UK Approves Leqembi for Long-Term Alzheimer's IV Treatment #United_Kingdom #Stockholm #Eisai #Leqembi #BioArctic

Thiard News@F4F

@newsen.bsky.social

4 months ago

BioArctic Expands Alzheimer's Treatment Portfolio with New Data and Partnerships BioArctic's recent report showcases significant advancements in Alzheimer’s treatments and collaborations, focusing on lecanemab's impact and new innovations.

BioArctic Expands Alzheimer's Treatment Portfolio with New Data and Partnerships #Sweden #Stockholm #Leqembi #BioArctic #Alzheimer’s_treatment

Thiard News@F4F

@newsen.bsky.social

4 months ago

BioArctic's Third Quarter Report: Growth and Innovative Partnerships in Alzheimer's Treatment BioArctic reports significant progress in Alzheimer's treatment developments, highlighting partnerships, revenue growth, and a promising pipeline of new projects.

BioArctic's Third Quarter Report: Growth and Innovative Partnerships in Alzheimer's Treatment #Sweden #Stockholm #Leqembi #BioArctic #Alzheimer’s_Disease

Thiard News@F4F

@newsen.bsky.social

5 months ago

Leqembi® Records Impressive Sales Growth of 18 Billion Yen in Q3 2025 Leqembi® has achieved a remarkable sales milestone, totaling 18 billion yen in the third quarter of 2025, marking a significant growth for the treatment of Alzheimer's disease.

Leqembi® Records Impressive Sales Growth of 18 Billion Yen in Q3 2025 #Sweden #Stockholm #Eisai #Leqembi #BioArctic

Thiard News@F4F

@newsen.bsky.social

5 months ago

Leqembi® Sees Impressive Revenue of 18 Billion Yen in Q3 2025 BioArctic and Eisai revealed Leqembi's remarkable sales in Q3 2025, totaling 18 billion yen, showcasing continued growth in Alzheimer's treatment.

Leqembi® Sees Impressive Revenue of 18 Billion Yen in Q3 2025 #Sweden #Stockholm #Eisai #Leqembi #BioArctic

Thiard News@F4F

@newsen.bsky.social

5 months ago

Health Canada Approves Leqembi®: A Revolutionary Treatment for Alzheimer's Disease Leqembi® (lecanemab) has received authorization from Health Canada, becoming a landmark treatment for Alzheimer's disease, targeting early stages of this condition.

Health Canada Approves Leqembi®: A Revolutionary Treatment for Alzheimer's Disease #Canada #Ontario #Leqembi #BioArctic #Alzheimer’s_Disease

Thiard News@F4F

@newsen.bsky.social

5 months ago

Leqembi®: A Significant Advancement in Alzheimer's Treatment in the Nordics Leqembi® becomes available in Finland for Alzheimer's treatment, marking a crucial step in combating early-stage Alzheimer's disease in the Nordics.

Leqembi®: A Significant Advancement in Alzheimer's Treatment in the Nordics #Finland #Leqembi #BioArctic #Helsinki #Alzheimer’s

Thiard News@F4F

@newsen.bsky.social

5 months ago

Leqembi Iqlik Receives TIME Recognition as a Top Innovation of 2025 Leqembi Iqlik, an innovative Alzheimer's treatment, has been listed among TIME's 2025 best inventions, showcasing its potential impact on healthcare.

Leqembi Iqlik Receives TIME Recognition as a Top Innovation of 2025 #Sweden #Stockholm #Eisai #Leqembi #BioArctic

Thiard News@F4F

@newsen.bsky.social

5 months ago

Leqembi Iqlik: Recognized by TIME as One of 2025's Best Innovations Leqembi Iqlik, an innovative Alzheimer’s treatment, has made it to TIME’s Best Inventions of 2025. Find out how this breakthrough is changing lives.

Leqembi Iqlik: Recognized by TIME as One of 2025's Best Innovations #Sweden #Stockholm #Eisai #Leqembi #BioArctic

Thiard News@F4F

@newsen.bsky.social

6 months ago

Eisai and BioArctic Celebrate Leqembi® Approval for Alzheimer’s Treatment in China Leqembi® (lecanemab) has received approval for IV maintenance therapy in China, marking a significant development in Alzheimer’s treatment.

Eisai and BioArctic Celebrate Leqembi® Approval for Alzheimer’s Treatment in China #China #Beijing #Lecanemab #Leqembi #BioArctic

Thiard News@F4F

@newsen.bsky.social

6 months ago

Leqembi® Receives Approval for IV Maintenance Treatment in China BioArctic's lecanemab (Leqembi) has been approved in China for IV maintenance treatment of early Alzheimer's disease, marking a significant advancement.

Leqembi® Receives Approval for IV Maintenance Treatment in China #China #Beijing #Leqembi #BioArctic #Alzheimer's

Thiard News@F4F

@newsen.bsky.social

6 months ago

Leqembi® Receives Approval in Australia for Early Alzheimer's Disease Treatment Australia's Therapeutic Goods Administration has approved lecanemab (Leqembi) for treating early Alzheimer's disease, marking a significant step forward in Alzheimer's care.

Leqembi® Receives Approval in Australia for Early Alzheimer's Disease Treatment #Australia #Leqembi #BioArctic #Alzheimer's_Disease #なし

Thiard News@F4F

@newsen.bsky.social

6 months ago

Leqembi® Receives Approval for Early Alzheimer's Treatment in Australia Leqembi, developed by BioArctic and Eisai, has been approved by Australia's TGA to treat early Alzheimer's disease in specific patients, emphasizing innovative solutions in healthcare.

Leqembi® Receives Approval for Early Alzheimer's Treatment in Australia #Stockholm #Australia #Eisai #Leqembi #BioArctic

Thiard News@F4F

@newsen.bsky.social

6 months ago

BioArctic's Gunilla Osswald Honored as Uppsala University's Alumnus of the Year 2025 Gunilla Osswald, CEO of BioArctic, has been recognized as Uppsala University's Alumnus of the Year 2025 for her impactful career in biopharma and innovative leadership.

BioArctic's Gunilla Osswald Honored as Uppsala University's Alumnus of the Year 2025 #Sweden #BioArctic #Uppsala #Gunilla_Osswald #Alumnus_of_the_Year

Thiard News@F4F

@newsen.bsky.social

6 months ago

Gunilla Osswald Recognized as Uppsala University Alumnus of the Year 2025 In 2025, Gunilla Osswald, CEO of BioArctic, was honored as Uppsala University's Alumnus of the Year for her contributions to science and society.

Gunilla Osswald Recognized as Uppsala University Alumnus of the Year 2025 #Sweden #BioArctic #Uppsala #Uppsala_University #Gunilla_Osswald